12.5 C
New York
Thursday, November 19, 2026

Prostate cancer test advice changes for US men

Must read

Rajiv
Rajivhttps://trendsnewsstories.com/
Rajiv writes and edits news and explainers for Trends News Stories, based in New Delhi, India.

The American Cancer Society has updated its advice on prostate cancer screening, recommending regular PSA blood tests for men in defined age and risk groups. The new guideline, released on 12 November 2026 and published in CA: A Cancer Journal for Clinicians, moves away from more than a decade of cautious guidance. Average-risk men aged 50 to 69 are now advised to have a PSA test every two years. Men at higher risk should start earlier, at 45, and be tested every year. The change rests on longer-term evidence that routine testing can cut deaths from prostate cancer, and on newer tools that help doctors tell dangerous tumours apart from slow-growing ones that may never cause harm.

Prostate cancer screening by age and risk

The guideline sets out a schedule that depends on age and risk. Men at average risk should have a PSA test every two years from age 50 to 69. Black men should be tested every year from age 45 to 69, as should non-Black men with a strong family history of prostate cancer. A strong family history means a father, brother or son diagnosed before the age of 65, or several first-degree relatives diagnosed at any age. Non-Black men with one first-degree relative diagnosed at 65 or older can start at 45 and be tested every two years. The schedule applies only after a clinician has confirmed that the man understands the benefits, limits and harms of testing.

The guideline also sets limits. Men aged 70 to 74 should make individual decisions after talking through the benefits and harms with a doctor. Routine prostate cancer screening is not recommended for men aged 75 to 79, although exceptionally healthy men in that age group may discuss continuing. Screening is discouraged for men aged 80 and older, and for any man with a life expectancy of less than 10 years. Men with known inherited gene changes, such as BRCA2, should discuss the timing and frequency of testing with a clinician. The previous guidance from the Society dated from 2010.

Prostate cancer and a high PSA reading

A PSA test measures a protein produced by the prostate gland. A raised reading can point to prostate cancer, but it can also result from a benign enlargement of the gland, inflammation, or other conditions that are not cancer. A single abnormal result therefore needs careful reading. The guideline says a PSA of 3.0 nanograms per millilitre or more at ages 45 to 69, or 6.5 nanograms per millilitre or more at ages 70 to 74, should prompt a repeat test within two weeks to three months. If the reading stays high, doctors may recommend a prostate MRI or biomarker testing before any biopsy is considered.

Not every tumour found by screening needs immediate treatment. Some prostate cancers grow so slowly that they may never cause symptoms or threaten a man’s health. For men diagnosed with low-risk prostate cancer, active surveillance can be an alternative to surgery or radiation. That means regular PSA measurements, clinical checks, imaging and sometimes repeat biopsies, with treatment considered only if the cancer shows signs of progression. The approach can help avoid or delay complications of treatment, including urinary incontinence, erectile dysfunction and bowel problems. The Society estimates 333,830 new cases of prostate cancer and 36,320 deaths in the United States in 2026. Black men face about 67 per cent higher incidence and nearly double the mortality rate of White men, a gap the new schedule is designed to narrow.

What Indian men should do

The guideline was written for the United States, and it should not be read as India’s national advice. India does not have population-based PSA screening, and the American schedule cannot be applied wholesale to Indian men. Decisions about testing should take account of age, family history, inherited genetic risk, overall health, and access to follow-up care such as MRI and biopsy. Men with a family history of prostate cancer, or with known inherited cancer-related gene changes, should discuss screening with a doctor rather than deciding on their own.

Men who notice persistent urinary symptoms, blood in the urine, or other worrying changes should seek medical advice rather than waiting until they reach a routine screening age. A PSA test is a starting point, not a diagnosis, and an abnormal result calls for a repeat test and further checks. The US Preventive Services Task Force, which issues separate advice, still leaves screening at ages 55 to 69 to individual choice under its 2018 recommendation, and its update is in progress. For Indian men, the practical step is a conversation with a doctor about personal risk, and about what follow-up care is available if a test comes back high.

More articles

Latest article